Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma - Drug Trials For Money - Paid Clinical Trials

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
Conditions:   Metastatic Angiosarcoma;   Metastatic Dedifferentiated Liposarcoma;   Metastatic Osteosarcoma;   Recurrent Angiosarcoma;   Recurrent Dedifferentiated Liposarcoma;   Recurrent Osteosarcoma;   Refractory Dedifferentiated Liposarcoma;   Refractory Osteosarcoma
Interventions:   Biological: Durvalumab;   Biological: Oleclumab
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 17, 2020 / by / in
Comments